Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 116 | NANETS2025 | Next issue

NANETS 2025

Trials In Progress

Section

Table of contents

ea0116t1 | Section

NETTER-3: [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, Grade 1/2 (Ki-67 <10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden

ea0116t2 | Section

STELLAR-311: A randomized phase 2/3 study of zanzalintinib versus everolimus in patients with previously treated advanced neuroendocrine tumors

ea0116t3 | Section

Obrixtamig (BI 764532) in relapsed/refractory delta-like ligand 3 (DLL3)-high extrapulmonary neuroendocrine carcinoma: Phase II DAREON®-5 dose-expansion trial in progress

ea0116t4 | Section

CAREFNDR: Phase 3, Randomized, Placebo-Controlled Study of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors

ea0116t5 | Section

Trial in progress: A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants with DLL3 positive Neuroendocrine Carcinomas (NECs) and other Selected Solid Tumors

ea0116t6 | Section

Multicenter Phase 2 Trial of Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors: interim report

ea0116t7 | Section

Trial-in-Progress: A Phase 2 Study of ONC206 in Patients with Advanced Pheochromocytoma and Paraganglioma

ea0116t8 | Section

NCI 10479: A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lu 177 Dotatate in SSTR+ Pancreatic Neuroendocrine Tumors

ea0116t9 | Section

Alliance A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor-Positive Bronchial Neuroendocrine Tumors

ea0116t10 | Section

NET RETREAT: a CCTG-SWOG Phase II Study of 177Lutetium-Dotatate Retreatment vs. Standard of Care in Metastatic GEPNET Patients

ea0116t11 | Section

A Phase 1 Trial of the Oncolytic Virus SVV-001 with Nivolumab and Ipilimumab in Patients with High Grade Neuroendocrine Neoplasms

ea0116t12 | Section

A Prospective Observational Study of GLP-1 and GLP-1/GIP Receptor Agonists in Patients with Well-Differentiated Neuroendocrine Tumors

ea0116t13 | Section

Stratification of Biochemical Response to Somatostatin Analogs in Carcinoid Syndrome: Implications for Risk of Carcinoid Heart Disease

ea0116t14 | Section

First-in-Human Study of a Novel Nonpeptide Drug Conjugate (CRN09682) in Patients With Somatostatin Receptor 2-Expressing Tumors

ea0116t15 | Section

ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2026 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more